Literature DB >> 302368

[The differentiation of human peripheral blood lymphocytes by immunological methods. III. Results in acute lymphoblastic leukemia (author's transl)].

C Pathouli, G Michlmayr, C Huber, R Kurz, H Haas, R Resch, M Falkensammer, K Abbrederis, H Huber, H Braunsteiner.   

Abstract

In 47 patients with acute lymphoblastic leukemia surface markers were evaluated on mononuclear cells of the peripheral blood as well as in some cases on bone marrow lymphocytes. The lymphocytes were characterized by their binding capacity for sheep red blood cells, the demonstration of Fc-receptors, complement receptors as well as surface immunoglobulins. In 6 of 23 untreated patients the blasts bound sheep red blood cells spontaneously (T-ALL), in two of these six cases the lymphoblasts had simultaneously receptors for complement. In a further patients the lymphoblasts had complement- and Fc-receptors. The blasts of 16 of 23 patients were negative in respect to the markers tested (O-ALL). By comparing two groups of patients--one with positive cells, one unreactive--the clinical features differed: the marker positive group showed a predominance of male patients, 5 of 7 patients had a massive mediastinal mass and the remission rate was lower than in the group with positive blasts. 24 patients in remission under maintance treatment had a decreased percentage of rosette forming lymphocytes as well as lymphocytes with surface immunoglobulins and Fc-receptors. There existed some correlation between the percentage of rosette forming lymphocytes and the clinical course: patients with complications had lower percentages of rosette forming lymphocytes than patients with a favourable course.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 302368     DOI: 10.1007/bf01482532

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  24 in total

1.  T and B lymphocyte markers on the neoplastic cell of 20 patients with acute and 10 patients with chronic lymphoid leukemia.

Authors:  D Belpomme; D Dantchev; E Du Rusquec; D Grandjon; R Huchet; P Pouillart; L Schwarzenberg; J L Amiel; G Mathé
Journal:  Biomedicine       Date:  1974-03

2.  T cell surface markers on lymphoblasts from acute lymphocytic leukemia.

Authors:  L Borella; L Sen
Journal:  J Immunol       Date:  1973-10       Impact factor: 5.422

3.  Evidence for B-cell origin of reticulum cell sarcoma.

Authors:  H Stein; E Kaiserling; K Lennert
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1974

4.  Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia.

Authors:  R J Aur; J Simone; H O Hustu; T Walters; L Borella; C Pratt; D Pinkel
Journal:  Blood       Date:  1971-03       Impact factor: 22.113

5.  [Differentiation of human blood lymphocytes using serologic and autoradiographic methods. II. Results in primary and symptomatic immunoglobulin deficiency conditions (author's transl)].

Authors:  C Huber; R Kurz; H Asamer; H Huber; H Braunsteiner
Journal:  Klin Wochenschr       Date:  1974-02-01

6.  [Rosette tests in lymphoproliferative diseases].

Authors:  G Michlmayr; C Pathouli; M Falkensammer; C Huber; H Huber; H Braunsteiner
Journal:  Schweiz Med Wochenschr       Date:  1976-06-05

Review 7.  B and T cell markers in human proliferative blood diseases and primary immunodeficiencies, with special reference to membrane bound immunoglobulins.

Authors:  M Seligmann; J L Preud'Homme; J C Brouet
Journal:  Transplant Rev       Date:  1973

8.  T and B lymphocytes in leukemia therapy.

Authors:  E Esber; W DiNicola; N Movassaghi; S Leikin
Journal:  Am J Hematol       Date:  1976       Impact factor: 10.047

9.  Clinical importance of lymphoblasts with T markers in childhood acute leukemia.

Authors:  L Sen; L Borella
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

10.  Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia.

Authors:  H M Grey; E Rabellino; B Pirofsky
Journal:  J Clin Invest       Date:  1971-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.